Natixis Advisors
CTKB icon

Natixis Advisors’s Cytek Biosciences CTKB Stock Holding History

Natixis Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,951
Closed -$201K – 1586
2024
Q2 		$201K Buy
+35,951
New +$216K ﹤0.01% 1573

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Natixis Advisors's CTKB Position: Q3 2024 in Review

Natixis Advisors sold out of Cytek Biosciences (CTKB) in Q3 2024, closing a stake of 35,951 shares — an estimated $201K sold.

Natixis Advisors first reported a position in CTKB in Q2 2024 and held it in 1 quarter. The position peaked at $201K in Q2 2024. 136 funds tracked by Wall St. Rank hold CTKB as of Q3 2024.

  • Natixis Advisors reported no remaining Cytek Biosciences position as of Q3 2024 after selling out during the quarter.
  • Natixis Advisors sold 35,951 Cytek Biosciences shares in Q3 2024, an estimated $201K.
  • Natixis Advisors first reported a position in Cytek Biosciences in Q2 2024 and held it in 1 quarter.
  • Natixis Advisors's Cytek Biosciences position peaked at $201K in Q2 2024.
  • 136 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2024.

Based on Natixis Advisors's 13F filing for Q3 2024, filed 6 Nov 2024.